IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Congress Park Capital LLC

Congress Park Capital LLC lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 5.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 450 shares of the company’s stock after selling 25 shares during the period. Congress Park Capital LLC’s holdings in IDEXX Laboratories were worth $250,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Moneta Group Investment Advisors LLC increased its holdings in IDEXX Laboratories by 121,647.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock valued at $3,038,192,000 after buying an additional 7,441,162 shares during the last quarter. Norges Bank bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $336,416,000. Morgan Stanley raised its position in shares of IDEXX Laboratories by 36.0% during the 4th quarter. Morgan Stanley now owns 986,232 shares of the company’s stock valued at $402,344,000 after acquiring an additional 260,926 shares in the last quarter. Alliancebernstein L.P. lifted its stake in IDEXX Laboratories by 6.4% during the second quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock worth $1,804,428,000 after purchasing an additional 214,529 shares during the last quarter. Finally, Winslow Capital Management LLC boosted its holdings in IDEXX Laboratories by 24.9% in the third quarter. Winslow Capital Management LLC now owns 689,873 shares of the company’s stock worth $301,661,000 after purchasing an additional 137,621 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In other news, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the transaction, the chief financial officer now owns 29,718 shares in the company, valued at approximately $16,939,557.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the transaction, the chief financial officer now owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,524 shares of company stock worth $24,871,960. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Trading Up 0.1 %

NASDAQ:IDXX opened at $539.93 on Monday. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The business has a fifty day moving average of $548.86 and a 200-day moving average of $502.94. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. The stock has a market cap of $44.84 billion, a price-to-earnings ratio of 53.62, a PEG ratio of 2.96 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last released its earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. IDEXX Laboratories’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company earned $2.05 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on IDXX. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Friday, January 5th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. BNP Paribas assumed coverage on IDEXX Laboratories in a research report on Thursday, December 7th. They set an “outperform” rating and a $602.00 price target on the stock. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research report on Tuesday, January 30th. Finally, The Goldman Sachs Group increased their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $591.50.

Get Our Latest Report on IDXX

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Featured Articles

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.